vs
Side-by-side financial comparison of Northwest Bancshares, Inc. (NWBI) and Vericel Corp (VCEL). Click either name above to swap in a different company.
Northwest Bancshares, Inc. is the larger business by last-quarter revenue ($175.1M vs $92.9M, roughly 1.9× Vericel Corp). Northwest Bancshares, Inc. runs the higher net margin — 28.9% vs 25.0%, a 3.9% gap on every dollar of revenue. Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs 33.7%).
Northwest Bank is a bank headquartered in Warren, Pennsylvania. It is the leading subsidiary of Northwest Bancshares, Inc., a bank holding company, and operates 151 branches in Pennsylvania, Western New York, Northeast Ohio, Appalachian Ohio, and Indiana.
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
NWBI vs VCEL — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $175.1M | $92.9M |
| Net Profit | $50.5M | $23.2M |
| Gross Margin | — | 78.7% |
| Operating Margin | — | 24.1% |
| Net Margin | 28.9% | 25.0% |
| Revenue YoY | — | 23.3% |
| Net Profit YoY | — | 17.3% |
| EPS (diluted) | $0.34 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $175.1M | — | ||
| Q4 25 | $179.9M | $92.9M | ||
| Q3 25 | $168.2M | $67.5M | ||
| Q2 25 | $150.4M | $63.2M | ||
| Q1 25 | $156.2M | $52.6M | ||
| Q4 24 | $154.3M | $75.4M | ||
| Q3 24 | $139.1M | $57.9M | ||
| Q2 24 | $98.0M | $52.7M |
| Q1 26 | $50.5M | — | ||
| Q4 25 | — | $23.2M | ||
| Q3 25 | $3.2M | $5.1M | ||
| Q2 25 | $33.7M | $-553.0K | ||
| Q1 25 | $43.5M | $-11.2M | ||
| Q4 24 | — | $19.8M | ||
| Q3 24 | $33.6M | $-901.0K | ||
| Q2 24 | $4.7M | $-4.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | 78.7% | ||
| Q3 25 | — | 73.5% | ||
| Q2 25 | — | 73.7% | ||
| Q1 25 | — | 69.0% | ||
| Q4 24 | — | 77.6% | ||
| Q3 24 | — | 71.9% | ||
| Q2 24 | — | 69.5% |
| Q1 26 | — | — | ||
| Q4 25 | 32.6% | 24.1% | ||
| Q3 25 | 2.1% | 5.1% | ||
| Q2 25 | 29.3% | -3.2% | ||
| Q1 25 | 36.2% | -24.3% | ||
| Q4 24 | 27.5% | 24.5% | ||
| Q3 24 | 31.3% | -4.3% | ||
| Q2 24 | 6.1% | -11.5% |
| Q1 26 | 28.9% | — | ||
| Q4 25 | — | 25.0% | ||
| Q3 25 | 1.9% | 7.5% | ||
| Q2 25 | 22.4% | -0.9% | ||
| Q1 25 | 27.8% | -21.4% | ||
| Q4 24 | — | 26.3% | ||
| Q3 24 | 24.2% | -1.6% | ||
| Q2 24 | 4.8% | -8.9% |
| Q1 26 | $0.34 | — | ||
| Q4 25 | $0.30 | $0.46 | ||
| Q3 25 | $0.02 | $0.10 | ||
| Q2 25 | $0.26 | $-0.01 | ||
| Q1 25 | $0.34 | $-0.23 | ||
| Q4 24 | $0.26 | $0.40 | ||
| Q3 24 | $0.26 | $-0.02 | ||
| Q2 24 | $0.04 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $286.7M | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.9B | $354.6M |
| Total Assets | $16.9B | $488.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $286.7M | — | ||
| Q4 25 | — | $137.5M | ||
| Q3 25 | — | $135.4M | ||
| Q2 25 | — | $116.9M | ||
| Q1 25 | — | $112.9M | ||
| Q4 24 | — | $116.2M | ||
| Q3 24 | — | $101.7M | ||
| Q2 24 | — | $102.5M |
| Q1 26 | $1.9B | — | ||
| Q4 25 | $1.9B | $354.6M | ||
| Q3 25 | $1.9B | $321.9M | ||
| Q2 25 | $1.6B | $306.8M | ||
| Q1 25 | $1.6B | $295.5M | ||
| Q4 24 | $1.6B | $292.0M | ||
| Q3 24 | $1.6B | $257.5M | ||
| Q2 24 | $1.6B | $243.0M |
| Q1 26 | $16.9B | — | ||
| Q4 25 | $16.8B | $488.0M | ||
| Q3 25 | $16.4B | $453.3M | ||
| Q2 25 | $14.5B | $435.6M | ||
| Q1 25 | $14.5B | $424.6M | ||
| Q4 24 | $14.4B | $432.7M | ||
| Q3 24 | $14.4B | $390.4M | ||
| Q2 24 | $14.4B | $376.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $15.0M |
| Free Cash FlowOCF − Capex | — | $12.8M |
| FCF MarginFCF / Revenue | — | 13.8% |
| Capex IntensityCapex / Revenue | — | 2.4% |
| Cash ConversionOCF / Net Profit | — | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | — | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $153.4M | $15.0M | ||
| Q3 25 | $41.9M | $22.1M | ||
| Q2 25 | $-2.3M | $8.2M | ||
| Q1 25 | $107.6M | $6.6M | ||
| Q4 24 | $127.7M | $22.2M | ||
| Q3 24 | $93.3M | $10.2M | ||
| Q2 24 | $40.7M | $18.5M |
| Q1 26 | — | — | ||
| Q4 25 | $141.8M | $12.8M | ||
| Q3 25 | $38.3M | $19.5M | ||
| Q2 25 | $-6.0M | $81.0K | ||
| Q1 25 | $105.8M | $-7.6M | ||
| Q4 24 | $125.4M | $8.5M | ||
| Q3 24 | $93.2M | $-9.2M | ||
| Q2 24 | $37.2M | $1.8M |
| Q1 26 | — | — | ||
| Q4 25 | 78.8% | 13.8% | ||
| Q3 25 | 22.8% | 28.8% | ||
| Q2 25 | -4.0% | 0.1% | ||
| Q1 25 | 67.7% | -14.5% | ||
| Q4 24 | 81.3% | 11.2% | ||
| Q3 24 | 67.0% | -15.9% | ||
| Q2 24 | 37.9% | 3.4% |
| Q1 26 | — | — | ||
| Q4 25 | 6.5% | 2.4% | ||
| Q3 25 | 2.2% | 3.9% | ||
| Q2 25 | 2.4% | 12.9% | ||
| Q1 25 | 1.2% | 27.0% | ||
| Q4 24 | 1.5% | 18.3% | ||
| Q3 24 | 0.1% | 33.5% | ||
| Q2 24 | 3.6% | 31.8% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.65× | ||
| Q3 25 | 13.24× | 4.35× | ||
| Q2 25 | -0.07× | — | ||
| Q1 25 | 2.48× | — | ||
| Q4 24 | — | 1.12× | ||
| Q3 24 | 2.77× | — | ||
| Q2 24 | 8.56× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NWBI
| Net Interest Income | $142.5M | 81% |
| Noninterest Income | $32.6M | 19% |
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
